Eli Lilly and Company (LLY)vsAtrium Therapeutics, Inc. Common Stock (RNA)
LLY
Eli Lilly and Company
$1,372.99
+6.57%
HEALTHCARE · Cap: $1.12T
RNA
Atrium Therapeutics, Inc. Common Stock
$8.40
+0.96%
HEALTHCARE · Cap: $131.20M
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 222201% more annual revenue ($79.67B vs $35.84M). LLY leads profitability with a 33.5% profit margin vs -184.1%. LLY earns a higher WallStSmart Score of 76/100 (B+).
LLY
Strong Buy76
out of 100
Grade: B+
RNA
Avoid32
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LLY.
Margin of Safety
+86.9%
Fair Value
$556.78
Current Price
$8.40
$548.38 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 79 in profit
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 54.2%
Revenue surging 47.7% year-over-year
Earnings expanding 26.2% YoY
Reasonable price relative to book value
Conservative balance sheet, low leverage
Areas to Watch
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 36.1x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -169.3% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 33.5% and operating margin at 54.2%. Revenue growth of 47.7% demonstrates continued momentum.
Bull Case : RNA
The strongest argument for RNA centers on Price/Book, Debt/Equity.
Bear Case : LLY
The primary concerns for LLY are Debt/Equity, P/E Ratio, Price/Book. A P/E of 42.2x leaves little room for execution misses. Debt-to-equity of 1.62 is elevated, increasing financial risk.
Bear Case : RNA
The primary concerns for RNA are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
LLY profiles as a growth stock while RNA is a turnaround play — different risk/reward profiles.
RNA carries more volatility with a beta of 0.93 — expect wider price swings.
LLY is growing revenue faster at 47.7% — sustainability is the question.
LLY generates stronger free cash flow (7.8B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 32/100), backed by strong 33.5% margins and 47.7% revenue growth. RNA offers better value entry with a 86.9% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Atrium Therapeutics, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Avidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies. The company is headquartered in La Jolla, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?